Work

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Year: 2020
Type: review
Abstract: Histone deacetylase (HDAC) enzymes play crucial roles in epigenetic gene expression and are an attractive therapeutic target. Five HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to poor single-agent drug efficacy and side effects associated with a lack of HDAC isoform or complex selectivity. An emerging strategy aiming to address these limitations is the development of bifunctional HDAC therapeutics-single molecules comprising a HDAC inhibitor conjugated to another specificity targeting moiety. This review summarises the recent advancements in novel types of dual-targeting HDAC modulators, including proteolysis-targeting chimeras (PROTACs), with a focus on HDAC isoform and complex selectivity, and the future potential of such bifunctional molecules in achieving enhanced drug efficacy and therapeutic benefits in treating disease.
Source: Molecules
Language: English
Open Access status: gold
Estimated APC paid: $2,112
OpenAlex ID: W3089079757
FWCI: 0.711
Cites: 202
Cited by: 48
Related to: 10